MDS Reports Third Quarter 2007 Results(scans. We experienced continued growt...),Health

We experienced continued growth in revenues from TheraSphere in the quarter compared to last year and demand for this product in Europe remains encouraging. TheraSphere has been added to treatment formularies in certain European countries, allowing doctors to charge for the utilization of the product. We are optimistic that this development will drive increased revenue from this radiotherapeutic product.

We announced a collaboration with the University of Ottawa Heart Institute in June to launch a molecular imaging centre of excellence to advance research in cardiology. We believe this collaboration represents a unique opportunity for future expansion of MDS Nordion's molecular imaging business. Also in the quarter, MDS Nordion was granted the C-TPAT Tier 3 designation for cross-border transportation of dangerous goods. This designation, which reflects the highest level of security clearance for transportation of dangerous goods, is a direct result of MDS Nordion's commitment to quality and safety and to the strength of our reputation with regulators in this area.

MDS Analytical Technologies

Financial Highlights

MDS Nordion

Financial Highlights

Third Quarter Year-to-Date

------------------------------- ----------------------

% Change % Change

---------------- --------

2007 2006 Reported Organic 2007 2006 Reported

-------------------------------------------------------------------------

$ 127 $ 66 92% 11% Net revenues $ 277 $ 184 51%

(71) (41) Cost of revenues (158) (112)

Selling, general,

(22) (6) and administration (41) (13)

R
'/>"/>